Therapeutic Use of Botulinum Toxin Type A in Treating Neck and Upper-Back Pain of Myofascial Origin: A Pilot Study Henry L. Lew, MD, PhD, Eun Ha Lee, MD, PhD, Annabel Castaneda, MD, MPH, Roger Klima, MD, Elaine Date, MD Archives of Physical Medicine and Rehabilitation Volume 89, Issue 1, Pages 75-80 (January 2008) DOI: 10.1016/j.apmr.2007.08.133 Copyright © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig 1 Flow of participants in the study. Archives of Physical Medicine and Rehabilitation 2008 89, 75-80DOI: (10.1016/j.apmr.2007.08.133) Copyright © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig 2 Mean changes in pain scores on the VAS from baseline (BTX-A vs control). Negative change indicates improved outcome. Archives of Physical Medicine and Rehabilitation 2008 89, 75-80DOI: (10.1016/j.apmr.2007.08.133) Copyright © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig 3 Improvement in mean scores on the SF-36 bodily pain scale from baseline (BTX-A vs control). *Statistically significantly better outcome for the BTX-A group (P<.025). Archives of Physical Medicine and Rehabilitation 2008 89, 75-80DOI: (10.1016/j.apmr.2007.08.133) Copyright © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions
Fig 4 Improvement in mean scores on the SF-36 mental health scale from baseline (BTX-A vs control). *Statistically significantly better outcome for the BTX-A group (P<.025). Archives of Physical Medicine and Rehabilitation 2008 89, 75-80DOI: (10.1016/j.apmr.2007.08.133) Copyright © 2008 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation Terms and Conditions